CD 154 Blockade Alters Innate Immune Cell Recruitment and Programs Alloreactive CD 8 + T Cells into KLRG-1 high Short-Lived Effector T Cells

CD154/CD40 blockade combined with donor specific transfusion remains one of the most effective therapies in prolonging allograft survival. Despite this, the mechanisms by which these pathways synergize to prevent rejection are not completely understood. Utilizing a BALB/c (H2-K) to B6 (H2-K) fully allogeneic skin transplant model system, we performed a detailed longitudinal analysis of the kinetics and magnitude of CD8 T cell expansion and differentiation in the presence of CD154/ CD40 pathway blockade. Results demonstrated that treatment with anti-CD154 vs. DST had distinct and opposing effects on activated CD44 CD62L CD8 T cells in skin graft recipients. Specifically, CD154 blockade delayed alloreactive CD8 T cell responses, while DST accelerated them. DST inhibited the differentiation of alloreactive CD8 T cells into multi-cytokine producing effectors, while CD40/CD154 blockade led to the diminution of the KLRG-1 long-lived memory precursor population compared with either untreated or DST treated animals. Moreover, only CD154 blockade effectively inhibited CXCL1 expression and neutrophil recruitment into the graft. When combined, anti-CD154 and DST acted synergistically to profoundly diminish the absolute number of IFN-c producing alloreactive CD8 T cells, and intra-graft expression of inflammatory chemokines. These findings demonstrate that the previously described ability of anti-CD154 and DST to result in alloreactive T cell deletion involves both delayed kinetics of T cell expansion and differentiation and inhibited development of KLRG-1 memory precursor cells. Citation: Ferrer IR, Wagener ME, Song M, Ford ML (2012) CD154 Blockade Alters Innate Immune Cell Recruitment and Programs Alloreactive CD8 T Cells into KLRG-1 Short-Lived Effector T Cells. PLoS ONE 7(7): e40559. doi:10.1371/journal.pone.0040559 Editor: Mehrdad Matloubian, University of California, San Francisco, United States of America Received March 16, 2012; Accepted June 8, 2012; Published July 5, 2012 Copyright: 2012 Ferrer et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Funding: This work was supported by National Institutes of Health grants AI073707 and AI079409 to Mandy L. Ford. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing Interests: The authors have declared that no competing interests exist. * E-mail: mandy.ford@emory.edu

[1]  K. Reimann,et al.  Nondepleting Anti‐CD40‐Based Therapy Prolongs Allograft Survival in Nonhuman Primates , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  J. Torras,et al.  In vivo therapeutic efficacy of intra-renal CD40 silencing in a model of humoral acute rejection , 2011, Gene Therapy.

[3]  M. Whitters,et al.  Selective CD28 Blockade Attenuates Acute and Chronic Rejection of Murine Cardiac Allografts in a CTLA‐4‐Dependent Manner , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  C. Larsen,et al.  Limiting the Amount and Duration of Antigen Exposure during Priming Increases Memory T Cell Requirement for Costimulation during Recall , 2011, The Journal of Immunology.

[5]  Xiu‐da Shen,et al.  Alloimmune Activation Enhances Innate Tissue Inflammation/Injury in a Mouse Model of Liver Ischemia/Reperfusion Injury , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  Nikhil S. Joshi,et al.  Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. , 2007, Immunity.

[7]  A. Kirk,et al.  CD154 Blockade, Sirolimus, and Donor-Specific Transfusion Prevents Renal Allograft Rejection in Cynomolgus Monkeys Despite Homeostatic T-Cell Activation , 2007, Transplantation.

[8]  W. Haining,et al.  Resolution of a chronic viral infection after interleukin-10 receptor blockade , 2006, The Journal of experimental medicine.

[9]  R. Strieter,et al.  Inhibition of Polymorphonuclear Leukocyte–Mediated Graft Damage Synergizes With Short-Term Costimulatory Blockade to Prevent Cardiac Allograft Rejection , 2005, Circulation.

[10]  A. Kirk,et al.  IDEC‐131 (Anti‐CD154), Sirolimus and Donor‐Specific Transfusion Facilitate Operational Tolerance in Non‐Human Primates , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  Philip F Halloran,et al.  Immunosuppressive drugs for kidney transplantation. , 2004, The New England journal of medicine.

[12]  M. Bevan,et al.  CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection , 2004, Nature Immunology.

[13]  K. Wood,et al.  Dependency of Direct Pathway CD4+ T Cells on CD40-CD154 Costimulation Is Determined by Nature and Microenvironment of Primary Contact with Alloantigen1 , 2004, The Journal of Immunology.

[14]  A. Rudensky,et al.  Mechanisms of donor-specific transfusion tolerance: preemptive induction of clonal T-cell exhaustion via indirect presentation. , 2003, Blood.

[15]  M. W. Flye,et al.  Donor-specific antigen transfusion-mediated skin-graft tolerance results from the peripheral deletion of donor-reactive CD8+ T cells , 2003, Transplantation.

[16]  E. Wherry,et al.  Viral Persistence Alters CD8 T-Cell Immunodominance and Tissue Distribution and Results in Distinct Stages of Functional Impairment , 2003, Journal of Virology.

[17]  M. Bevan,et al.  Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help , 2003, Science.

[18]  D. Greiner,et al.  Blockade of CD40-Mediated Signaling Is Sufficient for Inducing Islet But Not Skin Transplantation Tolerance 1 , 2003, The Journal of Immunology.

[19]  L. Wicker,et al.  NOD congenic mice genetically protected from autoimmune diabetes remain resistant to transplantation tolerance induction. , 2003, Diabetes.

[20]  R. Colvin,et al.  Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. , 2000, Nature medicine.

[21]  T. Strom,et al.  CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment. , 1999, Journal of immunology.

[22]  R. Noelle,et al.  Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4. , 1998, The Journal of clinical investigation.

[23]  Reinhold Förster,et al.  CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells , 1998, Nature.

[24]  D. Harlan,et al.  CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[25]  P. Linsley,et al.  Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[26]  A. Novick,et al.  Induction of chemokine gene expression during allogeneic skin graft rejection. , 1996, Transplantation.

[27]  P. Linsley,et al.  Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways , 1996, Nature.

[28]  R. Noelle,et al.  Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[29]  D. Greiner,et al.  Sufficient for Inducing Islet But Not Skin Blockade of CD 40-Mediated Signaling Is , 2003 .

[30]  Guohong Li,et al.  Copyright © American Society for Investigative Pathology DOI: 10.2353/ajpath.2008.070633 Vascular Biology, Atherosclerosis and Endothelium Biology CD40 Ligand Promotes Mac-1 Expression, Leukocyte Recruitment, and Neointima Formation after Vascular Injury , 2022 .